Glycoprotein 130 (gp130) is a key transmembrane protein required by IL‐6 receptor family members to engage in trans‐signaling, which triggers a pro‐inflammatory response.[33] Studies have indicated that sgp130Fc, which selectively binds to the IL‐6/sIL‐6R complex, significantly lowers IL‐6 levels in treated animals compared to placebo.[41] In our studies, we find that sgp130Fc treatment in hippocampus effectively alleviates the depression and anxiety behaviors induced by CSDS, and also alleviates atrocytes atrophy. The gene discussed is IL6R; the disease is depressive symptom measurement.